Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECURE
2022-501029-19-00Phase 4Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mepolizumab in eosinophilic asthma (EA) (4 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Composite primary endpoint: treatment compliance and asthma control at 6 months. Started Dec 2022; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2022-501029-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501029-19-00.